MedPath

NeurAxis Receives Expanded FDA Clearance for IB-Stim in Abdominal Pain Relief

• NeurAxis has secured an expanded FDA 510(k) clearance for its IB-Stim device, a non-implanted nerve stimulator, to broaden its application in functional abdominal pain relief. • The expanded clearance increases the addressable market for IB-Stim by approximately 75% and allows for the use of up to four devices per patient, according to NeurAxis. • IB-Stim utilizes percutaneous electrical nerve field stimulation (PENFS) technology to deliver gentle electrical impulses to cranial nerve bundles in the ear. • The American Medical Association has assigned IB-Stim to CPT Category I, effective January 2026, which is expected to increase revenue and margin growth for NeurAxis.

NeurAxis (NYSE:NRXS) has announced that the FDA has granted an expanded 510(k) clearance for its IB-Stim device, a non-implanted nerve stimulator used for functional abdominal pain relief. This clearance broadens the device's market reach and increases the potential number of devices used per patient.

IB-Stim Technology

The IB-Stim system employs NeurAxis's proprietary percutaneous electrical nerve field stimulation (PENFS) technology. It is now cleared for functional abdominal pain, building upon its existing clearance for irritable bowel syndrome (IBS)-associated pain in adolescents aged 8-21. The device delivers gentle electrical impulses to cranial nerve bundles in the ear.

Clinical Context and Market Impact

According to NeurAxis, there are currently no FDA-approved drug therapies specifically for children suffering from abdominal pain-related disorders linked to gut-brain interaction. Off-label drug treatments often carry the risk of significant side effects and lack robust scientific evidence supporting their efficacy.
Brian Carrico, President and CEO of NeurAxis, noted that the company has also received expanded payer coverage and a new reimbursement code. The American Medical Association has assigned IB-Stim to CPT Category I, effective January 2026. Carrico anticipates increased revenue and margin growth in the coming quarters as a result of these developments.

Expansion and Future Outlook

"We are excited to receive this new 510(k) clearance for IB-Stim, which expands the IB-Stim addressable market by roughly 75%," said Carrico. "Furthermore, we expect devices per patient to increase, as this new FDA clearance states on label use of four devices per patient. All of this has been achieved due to the strong body of published research, which has resulted in the increased acceptance of our PENFS technology."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

NextBioMedical's Nexsphere-F Receives FDA IDE Approval for Knee Osteoarthritis Trial

NextBioMedical's Nexsphere-F has received FDA IDE approval for a clinical trial (RESORB) to treat knee osteoarthritis via genicular artery embolization (GAE).
The RESORB trial is a multi-center, randomized, open-label study evaluating Nexsphere-F's efficacy in alleviating pain and improving mobility in OA patients.

FDA Fast-Tracks NeuroVive's Traumatic Brain Injury Drug

The FDA has granted Fast Track designation to NeuroVive's drug, NeuroSTAT, aimed at treating moderate to severe traumatic brain injury (TBI). This status accelerates the drug's development and review process, offering more frequent FDA interactions and feedback. NeuroSTAT works by protecting mitochondria, aiming to prevent secondary brain damage post-TBI, with hopes of improving survival, quality of life, and neurological function. Early trials have shown promising results, including a 35% decrease in brain injury volume in experimental models.

Pacira Receives FDA Clearance for Iovera System to Treat Chronic Back Pain

Pacira BioSciences has received FDA clearance for its Iovera system with a longer-needle Smart Tip to treat chronic low back pain, offering a drug-free alternative.
The Iovera system uses cryoneurolysis to temporarily halt nerve signals, providing pain relief that can last for months, and has shown benefits in a pilot study.

Nevro's HFX iQ Spinal Cord Stimulation System Receives CE Mark for Personalized Pain Relief

Nevro's HFX iQ spinal cord stimulation (SCS) system, leveraging AI and high-frequency therapy, has secured CE mark in Europe for personalized pain relief.
The HFX iQ system incorporates an implantable pulse generator (IPG), trial stimulator, and app, enabling real-time adjustments based on patient input.

NeurAxis' IB-Stim Receives FDA Clearance for Functional Abdominal Pain, Expanding Market

NeurAxis received FDA 510(k) clearance for IB-Stim, a non-implanted nerve stimulator, for functional abdominal pain relief, expanding its market by approximately 75%.
The new clearance allows for the use of four IB-Stim devices per patient, potentially increasing device utilization and revenue for NeurAxis.

NeurAxis' IB-Stim Receives FDA Clearance for Expanded Use in Pediatric IBS

NeurAxis received FDA 510(k) clearance for IB-Stim, expanding its market by approximately 75%.
The clearance extends the age range for IB-Stim use from 11-18 to 8-21 years old, broadening access.

FDA Grants Breakthrough Therapy Designation to Sanbexin Sublingual Tablets for Acute Ischemic Stroke

Simcere Pharmaceuticals' Sanbexin sublingual tablets receive Breakthrough Therapy designation from the FDA for acute ischemic stroke (AIS) treatment.
The designation is based on Phase III clinical trial data demonstrating significant improvements in neurological recovery and independent living ability compared to placebo.

Medtronic Gains FDA Approvals for Percept and Inceptiv Systems

Medtronic's Percept system, a 'pacemaker for the brain,' received FDA approval for managing movement disorders like Parkinson's disease by sending electrical signals to modulate brain rhythms.
The Inceptiv spinal cord stimulator, designed for chronic pain treatment, secured FDA approval with its unique ability to automatically adjust therapy, enhancing pain relief and maintaining stimulation levels.

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

NTX-001, a drug-device combination by Neuraptive Therapeutics, has received Breakthrough Therapy Designation from the FDA for treating peripheral nerve injuries requiring repair.
The designation was granted based on promising Phase 2 NEUROFUSE study results, potentially accelerating NTX-001's development and review process.

Medtronic's Inceptiv Spinal Cord Stimulator Receives FDA Approval for Chronic Pain Relief

Medtronic's Inceptiv, a spinal cord stimulator, has gained FDA approval for managing chronic pain by automatically adjusting stimulation based on biological signals.
The device is implanted and works by sensing signals and blocking pain signals before they reach the brain, offering a potential alternative to traditional pain management.

Reference News

[1]
NeurAxis wins expanded FDA clearance for non-implanted neurostim for pain relief
massdevice.com · Nov 4, 2024

NeurAxis receives expanded FDA 510(k) clearance for IB-Stim non-implanted nerve stimulator, enhancing market reach and d...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy